Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Protara Therapeutics has received a consensus rating of "Moderate Buy" from seven brokerages, with one sell rating, five buy ratings, and one strong buy rating.
• The stock has seen a 12-month price objective averaging $19.60, while currently trading at $4.82.
• Despite reporting a quarterly earnings beat with an EPS of ($0.35), analysts expect Protara to post -3.32 EPS for the current year.

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.60.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Protara Therapeutics in a research note on Saturday, September 27th.

Protara Therapeutics Stock Down 1.0%

TARA opened at $4.82 on Wednesday. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48. The stock has a market cap of $185.96 million, a price-to-earnings ratio of -2.98 and a beta of 1.53. The business has a 50 day moving average of $3.42 and a 200-day moving average of $3.44.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.08. As a group, analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of large investors have recently made changes to their positions in TARA. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics during the fourth quarter worth approximately $110,000. Charles Schwab Investment Management Inc. bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $64,000. American Century Companies Inc. bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $154,000. Walleye Capital LLC increased its stake in shares of Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock worth $977,000 after purchasing an additional 8,640 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Protara Therapeutics during the first quarter worth approximately $320,000. Institutional investors own 38.13% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.